of 133 patients with advanced urothelial tract cancer given methotrexate ( mtx ) , vinblastine ( vbl ) , adriamycin ( adr ) ( doxorubicin ; adria laboratories , columbus , oh ) , and cisplatin ( ddp ) ( m-vac regimen ) , significant tumor regression occurred in 72 % +/- 8 % of 121 with transitional cell carcinoma ( tcc ) evaluable for response .
C0042670
vinblastine
C0065452
m-vac regimen